Trinity Delta research note & consensus forecasts

Futura Medical PLC

11 September 2024

 

11 September 2024

Futura Medical plc

("Futura" or the "Company")

Trinity Delta research note and consensus forecasts

Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces the publication of an analyst report by Trinity Delta which is available on the Company's website: https://www.futuramedical.com/investor-centre/shareholder-centre/analyst-research/

Following the release of the updated research, the company confirms that the equity analyst consensus market expectations for revenue for the year ending 31 December 2024 and 31 December 2025 are £13.4 million and £18.6 million respectively.

Contacts:

Futura Medical plc	James Barder Chief Executive Officer Angela Hildreth Finance Director and COO	[e-mail] [phone] www.futuramedical.com
Panmure Liberum Nominated Adviser and Broker	Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking)	[phone]
Stifel Nicolaus Europe Limited Joint Broker	Alan Selby Ben Maddison	[phone]
Alma Strategic Communications	Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock	[phone] [e-mail]

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

 

END